Aldeyra Therapeutics Completes Enrollment for Phase 2 trial of ADX-2191 for Treatment of Retinitis Pigmentosa
Aldeyra Therapeutics, Inc. has announced the completion of the enrollment process for the Phase 2 Clinical Trial of ADX-2191 (methotrexate injection, USP), a potential treatment for retinitis pigmento ...
Anavex Announces Exceeding of Enrollment Target for the ANAVEX®2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial
Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company, announced that 92 patients with Rett syndrome have been enrolled in the ANAVEX®2-73 (blarcamesine) EXCELLENCE Phase 2/3 study in ...